NCT03649880View on ClinicalTrials.gov

Feasibility of FMISO in Brain Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2030

Conditions

Malignant Brain Neoplasm

Interventions

DRUG

¹⁸F-Fluoromisonidazole

Given IV

PROCEDURE

Computed Tomography

Undergo PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MRI or PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET/MRI

PROCEDURE

Oxygen Therapy

Receive supplemental oxygen

Trial Locations (1)

97239

RECRUITING

OHSU Knight Cancer Institute, Portland

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Oregon Health and Science University

OTHER

collaborator

Weill Cornell University

UNKNOWN

lead

OHSU Knight Cancer Institute

OTHER